Tianyin Pharma completes Jiangchuan macrolide facility construction

Jiangchuan macrolide facility holds both macrolide API production license from China’s State Food and Drug Administration (SFDA) and related business licenses from the Industry and Commerce Bureau and Tax department.

The completion of Phase I 240 ton capacity manufacturing facility will be followed by the SFDA’s GMP certification.

The facility is expandable to 500 ton total Phase II capacity and 900 ton total Phase III capacity of international standard Azithromycin active pharmaceutical ingredient (API) for both domestic and international market.

Azithromycin is said to inhibit the growth of bacteria by interfering with their protein synthesis via binding to the 50S subunit of the bacterial ribosome, and consequently inhibiting mRNA translation.

Tianyin said Azithromycin has been most effective against a broad spectrum of microorganisms such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenza, Neisseria gonorrhoeae, Chlamydia pneumonia, Chlamydia trachomatis, Mycoplasma pneumonia, Helicobacter pylori, Salmonella typhi and Mycobacterium avium intracellulare.

Tianyin specializes in the development, manufacturing, marketing and sale of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals.